Primer: Saint Bella (2508 HK) - Apr 2026
Saint Bella is a leading provider of premium postpartum care services in China, capitalizing on the rising demand for high-quality maternal and...
153 Views
APAC Healthcare Weekly (February 15)–Innovent Bio, InSilico, Eisai, Takeda, Alteogen, Pharmaessentia
Few Chinese biotech companies entered drug development collaborations. Eisai’s Leqembi autoinjector gets priority review in China. FDA will likely...
451 Views
HK IPO Essential Statistics: Quantifying Lock-Up Expiry Overhang
HK IPO Essential Stat: We studied 43 HK IPO cornerstone deals listed in 2025 to quantify the selling pressure upon lock-up expiry.
203 Views
Saint Bella (2508 HK): Strong Branding, Secular Demand In Place, 1H25 Results Affirms Growth Story
​Saint Bella reports 26% sales growth in 1H25 , driven by postpartum business as number of centers increased. The company will continue to deepen...
471 Views
Saint Bella: H1’25 Earnings Review - Clear Visibility on Strong Growth and Improving Profitability
​Saint Bella, a leading family care group in Asia, reported strong financial results for the six months ended 30 June 2025. The company prepares to...
603 Views